The teacher Paola Neri recently received the prestigious Ken Anderson Young Investigator Award during the 18th International Workshop on Multiple Myeloma, Vienna, Austria.
The award, conferred by an authoritative commission of international experts, represents an important recognition of the long research work carried out by Prof. Paola Neri in the field of translational research “from bench to bedside ”for the development of new strategies for the treatment of human tumors and in particular of multiple myeloma.
A long job that the same, originally from Marcellinara, in the province of Catanzaro, began very early as a student at the Magna Graecia University of Catanzaro, where she graduated and completed her specialization course in Medical Oncology and PhD in Molecular Oncology and Experimental Immunology. This initial training continued first at the Dana Farber Cancer Institute & Harvard Medical School, where he worked directly with Prof. Pierfrancesco Tassone, his mentor since the beginning of his university and research path, within the group of Prof. Kenneth Anderson, and later at the University of Calgary, Canada. At this leading Canadian University, Prof. Neri is currently Associate Professor of Medicine, attending physician of Hematology and active member of the Arnie Charbonneau Cancer Institute. Since 2019 he has been Scientific Director of the Precision Oncology Hub, Translational Research Laboratory, at the Tom Baker Cancer Center (TBCC), an institute of great international standing, in the same location.
The main objective of his research, since his first studies in the Oncology laboratories of the University of Catania, is the study of multiple myeloma with a particular interest in the genetic characteristics of the disease and the identification of new therapeutic targets for the development of new drugs for this still incurable disease.
Prof. has received numerous international grants including Myeloma Canada, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Canadian Institute of Health Research (CIHR), International Myeloma Society (IMS) and is currently a member of the American Society of Hematology and the scientific committee of Myeloma Canada.